Financial Performance - Revenue for Q3 2022 reached ¥198,658,228.89, an increase of 30.92% year-over-year[7] - Net profit attributable to shareholders was ¥49,601,390.11, up 123.79% compared to the same period last year[7] - Net profit excluding non-recurring gains and losses was ¥45,622,308.85, reflecting a growth of 111.19% year-over-year[7] - Basic earnings per share for Q3 2022 was ¥0.21, up 61.54% from the same period last year[7] - For the first three quarters of 2022, the company reported total revenue of CNY 573.43 million, up 22.47% year-on-year[29] - The net profit attributable to shareholders for the first three quarters was CNY 127.16 million, an increase of 60.21% compared to the previous year[29] - The company reported a total comprehensive income of ¥127,739,140.77, up from ¥79,453,880.62, marking an increase of 60.8%[52] Assets and Equity - Total assets at the end of the reporting period amounted to ¥1,985,620,844.01, representing a 110.89% increase from the previous year[7] - Shareholders' equity reached ¥1,807,036,365.30, a significant rise of 154.53% compared to the end of the previous year[7] - The total assets of the company reached CNY 1.99 billion as of September 30, 2022, compared to CNY 941.52 million at the start of the year[40] - Total equity attributable to shareholders of the parent company increased significantly to ¥1,807,036,365.30 from ¥709,958,986.51, representing a growth of 154.5%[46] Cash Flow - Cash flow from operating activities for the year-to-date was ¥97,054,451.32, an increase of 70.49% year-over-year[7] - Net cash flow from operating activities rose by 70.49% to ¥97,054,451.32, primarily driven by increased cash receipts from sales[16] - Operating cash inflow totaled $571,083,668.76, an increase from $450,506,088.42 in the previous period, reflecting a growth of approximately 27%[57] - The net cash flow from financing activities was $893,059,310.56, contrasting with a net outflow of -$28,849,751.10 in the previous period, highlighting improved financial stability[60] - The company reported a net increase in cash and cash equivalents of $288,199,555.88, compared to a decrease of -$11,424,367.63 previously, indicating a positive cash position[60] Investments and Expenses - The company reported a 426.32% increase in contract assets, totaling ¥15,996,718.49, due to progress in R&D projects[12] - Management expenses increased by 30.03% to ¥41,727,809.43 due to higher employee compensation and listing-related costs[16] - Financial expenses decreased by 66.07% to ¥1,163,180.07 as a result of reduced bank loan interest after repayment[16] - Investment income surged by 2016.84% to ¥1,969,614.16 due to increased returns from financial products purchased with idle funds[16] - Research and development expenses rose to ¥25,220,770.88, an increase of 13.5% compared to ¥22,318,014.11 in the previous year[47] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,418[20] - Major shareholder Zheng Hanjie holds 20.77% of shares, totaling 49,098,900 shares[20] Tax and Liabilities - The company reported a 76.34% increase in income tax expenses to ¥23,848,515.01 due to profit growth[16] - Total liabilities decreased to ¥178,728,524.91 from ¥231,714,080.57, reflecting a reduction of approximately 22.9%[46] Product Performance - The core product "Aiting Jiu" (Dapoxetine Hydrochloride Tablets) generated sales of CNY 163.84 million, a 65.87% increase year-on-year[32] - The "He Wei Zheng Chang Wan" (Stomach and Intestine Pills) achieved sales of CNY 100.87 million, growing by 26.75% year-on-year[32] - The company is facing supply chain challenges for its core product "He Wei Zheng Chang Wan" due to domestic pandemic fluctuations and logistics issues[32]
泰恩康(301263) - 2022 Q3 - 季度财报